2020 Specialty Approvals – 96% via Limited Distribution
The FDA actually did a remarkable job in 2020 approving new drugs. In spite of the pandemic they managed to approve 53 novel drugs. That’s
January 15, 2021
The FDA actually did a remarkable job in 2020 approving new drugs. In spite of the pandemic they managed to approve 53 novel drugs. That’s
WOW….. Centene is ponying up $2.2 billion to acquire Magellan Health! This comes on the heels of Centene’s recently announced acquisition of PANTHER Rx only
We recently sent an RxReport detailing the FDA approval of Orgovyx as the last FDA approval in 2021. That was technically correct….. but there is
The FDA approved the last specialty therapy for 2020 just in time for Christmas. The new oral drug, Orgovyx from four-year-old Myovant Sciences, is indicated
December 29, 2020Winter Garden, FL More catching up —The FDA approved another specialty therapy earlier this month. The new approval is Margenza (margetuximab-cmkb) from MacroGenics and
There really hasn’t been a lot of good news in the specialty pharmacy industry this year. Demand has been down due to the virus. Increasing
This year saw few specialty pharmacy acquisitions…. but that just changed with the announcement by Centene Corporation that it has acquired PantherRx Rare Pharmacy. Terms
Someone must have lit a fire under the FDA new drug approval elves in the last few weeks as the activity level there suddenly boomed.
We ran across a press release recently that looked a tad odd. It appeared that the FDA had approved a new therapy, Alkindi Sprinkle from
Earlier this month the FDA approved yet another orphan drug, Orladeyo (berotralstat) from BioCryst Pharmaceuticals. It obtained an indication for the prevention of hereditary angioedema
